Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder

Exclusion Criteria

• •Unstable medical illness, including renal failure or dialysis;
• •Myocardial infarction within 6 months;
• •Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;
• •A need for prn benzodiazepines, another antiepileptic medication, or an anticipated change in the dose of any concomitant medications while receiving treatment with levetiracetam;
• •Clinically significant suicidality, including a suicide attempt within the past two months;
• •Lifetime history of DSM-IV dementia, schizophrenia, or any other DSM-IV psychotic disorder that is not attributable to BDD;
• •Current or recent (past 3 months) DSM-IV substance abuse or dependence;
• •Initiation of ongoing psychotherapy from a mental health professional within 3 months prior to study baseline;
• •Ongoing cognitive-behavioral therapy from a mental health professional;
• •Previous treatment with levetiracetam;
• •Treatment with investigational medication, depot neuroleptics, or ECT within the past 3 months.